OrthoPediatrics (KIDS) AI Stock Analysis

0 Followers

OrthoPediatrics

(BMV:KIDS)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Revenue Growth and Gross MarginsSustained revenue expansion alongside consistently high gross margins indicates strong demand for the pediatric-focused portfolio and meaningful product economics. This combination gives OrthoPediatrics resources to invest in commercial expansion, innovation, and surgeon adoption while supporting scalable growth.

Negative Factors

Persistent Net and Operating LossesDespite strong sales growth and narrowing losses, the company has not yet demonstrated durable earnings power. Persistent operating and net losses can constrain internally funded investment, leave profitability sensitive to expense growth, and make future performance dependent on continued operating leverage.

OrthoPediatrics Business Overview & Revenue Model

Company Description

OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children af...

OrthoPediatrics Earnings Call Summary

Earnings Call Date:Oct 26, 2026(Q3-2026)|Next Earnings Date:Mar 09, 2027

Earnings Call SentimentPositive

The call was strongly positive, with record revenue, 19% quarterly growth, a raised full-year revenue outlook, record adjusted EBITDA, positive quarterly free cash flow, strong demand across core businesses, and substantial progress in product launches and clinic expansion. The main challenges were that many super-cycle products remain in limited launch, eLLi commercialization is largely a 2028-2029 opportunity, year-to-date free cash flow remains negative, and operating expenses and commissions increased. Overall, the breadth and magnitude of the reported growth and management's confidence outweighed the timing and investment-related challenges.

Positive Updates

Record Quarterly Revenue and Broad-Based Growth

Third-quarter 2026 revenue reached a record $72.7 million, up 19% from $61.2 million in the prior-year period. Growth was driven by strong demand across implants and OPSB, trauma and deformity, scoliosis, international operations, legacy portfolio share gains, and new product contributions.

Negative Updates

Many Super-Cycle Products Are Still in Limited Launch

Many products in the super cycle remain in the very early stages of full market release or limited launch and are not yet meaningfully contributing to growth. Management said some products are not expected to contribute significant revenue in 2026.

Company Guidance

The company raised full year 2026 revenue guidance to the range of $270 million to $273 million, representing growth of 14% to 16%, reiterated adjusted EBITDA guidance of approximately $25 million, and continues to expect to deploy approximately $10 million in sets and achieve free cash flow break-even or better in 2026, with free cash flow positive in 2027 and beyond; year to date free cash flow was about $6 million of usage, requiring $6 million of positive free cash flow in the fourth quarter to reach breakeven or better for the year, and fourth-quarter gross margin was projected at 73%.

OrthoPediatrics Risk Analysis

OrthoPediatrics disclosed 79 risk factors in its most recent earnings report. OrthoPediatrics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

OrthoPediatrics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:KIDS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMED	87Outperform	$10.67B	20.05	11.59%	―	19.74%	51.10%
ZBH	69Neutral	$18.57B	23.50	6.36%	0.99%	8.62%	0.09%
OFIX	55Neutral	$356.41M	-5.70	-14.05%	―	2.99%	51.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENOV	50Neutral	$1.19B	-1.08	-68.17%	―	4.89%	-30.14%
ATEC	49Neutral	$1.13B	-13.34	-547.17%	―	15.34%	46.31%

* Healthcare Sector Average

Performance Comparison

MX:KIDS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
ATEC	Alphatec	7.47	-12.25	-62.12%
ENOV	Enovis Corporation	20.89	-10.60	-33.66%
OFIX	Orthofix Medical Inc.	8.76	-6.21	-41.48%
ZBH	Zimmer Biomet Holdings	97.06	10.44	12.05%
GMED	Globus Medical	79.58	18.07	29.38%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

OrthoPediatrics AI Stock Analysis